“Why Dutch hospitals are so good at beating superbugs”

It is with great pleasure that I ask your attention for this article that appeared in the Economist. Yes, we still have low resistance rates in our hospitals and if you’re interested in how that happened, read it. The prosaic composition contains two parts; a very realistic thriller-like opening, followed by a second part with a rather unrealistic explanation. Both parts are separated by a short sentence of absolute nonsense. Time for a review. Continue reading

Advertisements

The future of infection surveillance is ….. Google

If you feel that your  hospitals’ Electronic Health Record (EHR) can do more for you, read this. Not yet peer-reviewed, but still very impressive. Using all 46 billion (!) data points in the EHR from 216.221 patients in 2 hospitals they predicted (at day 1 of admission) in-hospital mortality, long length of stay and readmission, pretty accurately, and much better than existing prediction models. How? Deep learning techniques. Who are they? The paper has 35 authors, of which 32 work at Google Inc, Mountain View, California. Continue reading

What’s up for 2018?

I hope you enjoyed Christmas time and wish you all the best for this year. From my side, I will continue to reflect what I meet professionally, what surprises me, confirms what I thought to know or what confirms my ignorance. In 2017 I did that 41 times (a surprise to me!) and here are some trending topics that will most likely return in 2018. Continue reading

The antibiotic resistance crisis resolved by bacteriophages

I am regularly asked why we don’t treat infections caused by multidrug resistant bacteria with bacteriophages. Last Friday, the same question made it to the best viewed talkshow on Dutch television (The World Turns On), and in about 10 minutes the global threat of antibiotic resistance was resolved. Here is how….  Continue reading

Publish or perish

Our careers (at least partly) depend on our publications. The more, the better and to suit our needs we have a journal for any kind of publication. Sometimes, you read something and you may think “Hey, I have seen that before”. If the new study than confirms a previous finding, we apparently have a reproducible fact, which increases the likelihood that it is indeed true. Here is an example. Or not? Continue reading

Synbiotics and neonatal sepsis

With this blog I am leaving my beaten path: neonatal sepsis and probiotics. But so does this double-blind placebo-controlled study published today in Nature. To me, probiotics are still “something promising since 25 years”, without ever having substantiated that promise (like Ajax and the Chicago Cubs, until recently). In fact, colleagues of mine once led a study in which probiotics apparently killed patients with acute pancreatitis. This new study may change my view completely.

Continue reading

Sloppy science & good read

I’m packing for vacation. The book that I will NOT pack is: Rigor Mortis, how sloppy science creates worthless cures, crushes hope and wastes billions by Richard Harris. I read it already two times, and anyone interested in science, or trying to deliver a piece of it once in a while, should read it. It makes you realise what we do, what we publish and what we read. And then, it makes you humble (or sad, or furious, or happy). Continue reading